About EUSA | People | Portfolio | Partners & Investors | News | Site Map | Contact

Products

ProstaScint®

ProstaScint® is an imaging agent that can help locate and identify previously diagnosed prostate cancer. ProstaScint® is a monoclonal antibody combined with a small amount of radioactive material called indium-111 (In 111). As ProstaScint® circulates through the body, it attaches to Prostate Specific Membrane Antigen (PSMA) which is located on prostate cancer cells. These areas of attachment are visible to a gamma camera that can detect radiation given off by the indium-111. Using this technology, pictures or images will be produced showing prostate cancer.

ProstaScint®  is available in the U.S. For more information on ProstaScint®  please visit www.prostascintimaging.com.

For information on our products, where they are available and prescribing information, please see the Product Summary table.

Download pdf
PI: Download PDF

 

ProstaScint®

 

Portfolio
Caphosol®
Collatamp®
Erwinase®
Fomepizole
Kidrolase®
ProstaScint®
Quadramet®
Rapydan®
Xenazine®

Product Summary

Pipeline

Business Development
Opportunities

 

 
Back to home page Legal | Privacy Policy
Registered in England 4555273 Registered Office The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA Vat Registration No: 896 1192 88
©Eusa Pharma (Europe) Ltd. All rights reserved.